Investor directory

Venture Investors

Venture Investors, LLC is a venture capital firm based in Madison, Wisconsin, with additional offices in Ann Arbor and Milwaukee. Established in 1982, the firm specializes in seed, early-stage, and growth-stage financing, particularly targeting the healthcare and technology sectors. It invests in a range of areas including biotechnology, diagnostics, therapeutics, and medical devices, as well as in agriculture, clean technology, and engineering. The firm is particularly focused on opportunities arising from university technology transfer, leveraging its connections with research institutions in the Midwest. Venture Investors typically makes initial investments ranging from $0.25 million to $2.5 million, with lifetime investments between $5 million and $8 million. The firm aims to be the lead investor, preferring to invest in preferred stock or debt with warrant coverage, and generally holds its investments for five to seven years until an exit occurs through an initial public offering or sale. With over $200 million in assets under management, Venture Investors is dedicated to nurturing innovative ideas that advance health and wellness.

Focus

Series AEarly VentureScale StagemHealthHealth CareShow more
http://www.ventureinvestors.com
https://crunchbase.com/organization/venture-investors
https://linkedin.com/company/venture-investors
https://pitchbook.com/profiles/investor/11327-32
https://twitter.com/vi_funds
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=23757
https://www.privateequityinternational.com/database/#/profile?id=7501

Jim Adox

Executive Managing Director

James R. Adox

Executive Managing Director

David Arnstein

CFO

Martin C. Bear

Member of Advisory Board

Scott Button

Managing Director

John Neis

Managing Director

Weiss, Paul M. K.

Managing Director

Past deals in Laser

ViaLase

Series A in 2021
ViaLase develops an image-guided femtosecond laser surgical system for the treatment of glaucoma. ViaLase is headquartered in Corona Del Mar, California.

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Eximis Surgical

Series A in 2020
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.

HistoSonics

Series C in 2019
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Eximis Surgical

Venture Round in 2018
Eximis Surgical is developing an enabling technology that allows surgeons to quickly remove large specimens through small incisions. Its technology uses RF energized cutting wires temporarily held in place within a containment bag. It was founded in 2014 and headquartered in Louisville, Colorado.

HistoSonics

Series B in 2017
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

HistoSonics

Series A in 2014
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

HistoSonics

Series A in 2010
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Alcon LenSx

Series B in 2009
LensX Lasers is a maker of surgical lasers used to repair cataracts.

IntraLase Corporation

Venture Round in 2000
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Alfalight

Series A in 2000
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.